Inpatient and Outpatient Orderable

COVID-19 Antibody (Nucleocapsid) Build info

Synonyms

  • COVID-19 NUCLEOCAPSID ANTIBODY
  • COVIDNCAB
  • SARS-COV-2
  • LAB10454

Procedure Name

COVID-19 NUCLEOCAPSID ANTIBODY

Procedure Master Number

LAB10454

Cerner Name

Procedure ID

111412

Clinical Info

This test is intended for use as an aid in identifying individuals with an adaptive immune response to SARS‑CoV‑2, indicating recent or prior infection.

Specimen Sources

 Blood, Arterial Blood, Capillary Blood, Central Line Blood, Venous

Specimen Types

 Blood

Container

Gold or Lithium Heparin (Mint-green) top tube

Collection Instructions

Specimen: 1.0 mL serum or plasma (0.5 mL min)

Specimen Volume

1.0 mL serum or plasma (0.5 mL min)

Transport Instructions

Refrigerated

Specimen Stability

14 Days Room Temperature
14 Days Refrigerated
6 Months Frozen

Methodology

Electrochemiluminescence Immunoassay 

Days Performed

Sunday - Saturday
TAT: 2 Days

Performing Laboratory

Northwell Health Laboratories

CPT

86769

PDM

 2153035

Only Orderable at Locations:

 Orderable Everywhere

Results
Component Name Base Name Common Name External Name
COVID-19 NUCLEOCAPSID TOTAL ANTIBODY COVID19NCAB COVID 19 NUCLEOCAPSID TOTAL ANTIBODY COVID-19 Nucleocapsid Total Antibody
COVID-19 NUCLEOCAPSID ANTIBODY INTERPRETATION COVID19ABINT COVID 19 NUCLEOCAPSID AB INTERPRETATION COVID-19 Nucleocapsid Total Antibody Interpretation

Result Interpretation

    Instrument       Methodology   Anti-SARS-CoV-2 Antibody Interpretation
Roche 801 (Elecsys Anti-SARS-CoV-2 ) Electrochemiluminescence immunoassay COI < 1.0 : Non-reactive for  anti-SARS-CoV-2 antibodies
COI ≥ 1.0 : Reactive for anti-SARS-CoV-2 antibodies

The Roche Elecsys Anti‑SARS‑CoV‑2 nucleocapsid assay has been approved by the FDA for Emergency Use Authorization only. It has been validated to be accurate by Northwell Health Laboratories.

Positive results indicate that antibodies against SARS-CoV-2 were detected in your blood. Presence of antibodies to SARS‑CoV‑2 may not guarantee protection from SARS-CoV-2 reinfection.

Negative results do not preclude SARS‑CoV‑2 infection and should not be used as the sole basis for patient management decisions. A negative result can occur if the quantity of the anti‑SARS‑CoV‑2 antibodies is below the detection limits of the assay, or the antibodies that are detected are not present during the stage of disease in which a sample is collected. Follow-up testing with a molecular diagnostic tets should be considered to rule out infection in these individuals

 

Forms
edit